Evidence map›Paper›PMID 26005723›Full record

ArticleInternational journal of molecular medicine2015

Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells.

Lingmei Li, Lisha Qi, Zhijie Liang, Wangzhao Song, Yanxue Liu, Yalei Wang, Baocun Sun, Bin Zhang, Wenfeng Cao

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 107 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lingmei LiDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Lisha QiDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Zhijie LiangDepartment of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Wangzhao SongDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Yanxue LiuDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Yalei WangDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Baocun SunDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Bin ZhangDepartment of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Wenfeng CaoDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Tianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial-mesenchymal transition (EMT), a process closely related to tumor development, is regulated by a variety of signaling pathways and growth factors, such as transforming growth factor-β1 (TGF-β1) and epidermal growth factor (EGF). Hyaluronan (HA) has been shown to induce EMT through either TGF-β1 or EGF signaling and to be a regulator of the crosstalk between these two pathways in fibroblasts. In this study, in order to clarify whether HA has the same effect in tumor cells, we utilized the lung cancer cell line, A549, and the breast cancer cell line, MCF-7, and found that the effects of stimulation with TGF-β1 were more potent than those of EGF in regulating the expression of EMT-associated proteins and in enhancing cell migration and invasion. In addition, we observed that TGF-β1 activated EGF receptor (EGFR) and its downstream AKT and extracellular signal-regulated kinase (ERK) pathways. Furthermore, we found that TGF-β1 upregulated the expression of hyaluronan synthases (HAS1, HAS2 and HAS3) and promoted the expression of CD44, a cell surface receptor for HA, which interacts with EGFR, resulting in the activation of the downstream AKT and ERK pathways. Conversely, treatment with 4-methylumbelliferone (4-MU; an inhibitor of HAS) prior to stimulation with TGF-β1, inhibited the expression of CD44 and EGFR, abolished the interaction between CD44 and EGFR. Furthermore, the use of shRNA targeting CD44 impaired the expression of EGFR, deactivated the AKT and ERK pathways, reversed EMT and decreased the migration and invasion ability of cells. In conclusion, our data demonstrate that TGF-β1 induces EMT by the transactivation of EGF signaling through HA/CD44 in lung and breast cancer cells.

Indexed as

Breast NeoplasmsCell Line, TumorCell MovementEnzyme ActivationEpidermal Growth FactorEpithelial-Mesenchymal TransitionErbB ReceptorsExtracellular Signal-Regulated MAP KinasesFemaleGlucuronosyltransferaseHumansHyaluronan ReceptorsHyaluronan SynthasesHyaluronic AcidHymecromoneLung NeoplasmsCD44 protein, humanEGFR protein, humanEpidermal Growth FactorErbB ReceptorsExtracellular Signal-Regulated MAP KinasesGlucuronosyltransferaseHAS1 protein, humanHAS2 protein, humanHAS3 protein, humanHyaluronan ReceptorsHyaluronan SynthasesHyaluronic AcidHymecromoneProto-Oncogene Proteins c-aktRNA, Small InterferingTransforming Growth Factor beta1

Identifiers

PMID26005723
PMCPMC4494581
OpenAlexW1923318030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.